147 related articles for article (PubMed ID: 10425523)
1. Amino acids within the extracellular matrix (ECM) binding region (201-218) of rat insulin-like growth factor binding protein (IGFBP)-5 are important determinants in binding IGF-I.
Bramani S; Song H; Beattie J; Tonner E; Flint DJ; Allan GJ
J Mol Endocrinol; 1999 Aug; 23(1):117-23. PubMed ID: 10425523
[TBL] [Abstract][Full Text] [Related]
2. Binding of insulin-like growth factor (IGF)-binding protein-5 to smooth-muscle cell extracellular matrix is a major determinant of the cellular response to IGF-I.
Parker A; Rees C; Clarke J; Busby WH; Clemmons DR
Mol Biol Cell; 1998 Sep; 9(9):2383-92. PubMed ID: 9725901
[TBL] [Abstract][Full Text] [Related]
3. Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein 5 alters heparin binding and its change in affinity for IGF-I response to heparin.
Arai T; Clarke J; Parker A; Busby W; Nam T; Clemmons DR
J Biol Chem; 1996 Mar; 271(11):6099-106. PubMed ID: 8626396
[TBL] [Abstract][Full Text] [Related]
4. Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and -5 markedly reduce IGF-I binding and alter their biologic actions.
Imai Y; Moralez A; Andag U; Clarke JB; Busby WH; Clemmons DR
J Biol Chem; 2000 Jun; 275(24):18188-94. PubMed ID: 10766744
[TBL] [Abstract][Full Text] [Related]
5. Binding of mutants of human insulin-like growth factor II to insulin-like growth factor binding proteins 1-6.
Bach LA; Hsieh S; Sakano K; Fujiwara H; Perdue JF; Rechler MM
J Biol Chem; 1993 May; 268(13):9246-54. PubMed ID: 7683646
[TBL] [Abstract][Full Text] [Related]
6. Overlap of IGF- and heparin-binding sites in rat IGF-binding protein-5.
Song H; Beattie J; Campbell IW; Allan GJ
J Mol Endocrinol; 2000 Feb; 24(1):43-51. PubMed ID: 10656996
[TBL] [Abstract][Full Text] [Related]
7. Specific amino acid substitutions determine the differential contribution of the N- and C-terminal domains of insulin-like growth factor (IGF)-binding protein-5 in binding IGF-I.
Shand JH; Beattie J; Song H; Phillips K; Kelly SM; Flint DJ; Allan GJ
J Biol Chem; 2003 May; 278(20):17859-66. PubMed ID: 12626499
[TBL] [Abstract][Full Text] [Related]
8. Cumulative mutagenesis of the basic residues in the 201-218 region of insulin-like growth factor (IGF)-binding protein-5 results in progressive loss of both IGF-I binding and inhibition of IGF-I biological action.
Allan GJ; Tonner E; Szymanowska M; Shand JH; Kelly SM; Phillips K; Clegg RA; Gow IF; Beattie J; Flint DJ
Endocrinology; 2006 Jan; 147(1):338-49. PubMed ID: 16195401
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs.
Oh Y; Müller HL; Lee DY; Fielder PJ; Rosenfeld RG
Endocrinology; 1993 Mar; 132(3):1337-44. PubMed ID: 7679979
[TBL] [Abstract][Full Text] [Related]
10. Heparin-binding, highly basic regions within the thyroglobulin type-1 repeat of insulin-like growth factor (IGF)-binding proteins (IGFBPs) -3, -5, and -6 inhibit IGFBP-4 degradation.
Fowlkes JL; Thrailkill KM; George-Nascimento C; Rosenberg CK; Serra DM
Endocrinology; 1997 Jun; 138(6):2280-5. PubMed ID: 9165012
[TBL] [Abstract][Full Text] [Related]
11. Identification of the extracellular matrix binding sites for insulin-like growth factor-binding protein 5.
Parker A; Clarke JB; Busby WH; Clemmons DR
J Biol Chem; 1996 Jun; 271(23):13523-9. PubMed ID: 8662813
[TBL] [Abstract][Full Text] [Related]
12. Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth.
Nam TJ; Busby WH; Rees C; Clemmons DR
Endocrinology; 2000 Mar; 141(3):1100-6. PubMed ID: 10698186
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor (IGF)-binding protein-5-(201-218) region regulates hydroxyapatite and IGF-I binding.
Campbell PG; Andress DL
Am J Physiol; 1997 Nov; 273(5):E1005-13. PubMed ID: 9374688
[TBL] [Abstract][Full Text] [Related]
14. Role of insulin-like growth factor binding proteins in the control of IGF actions.
Clemmons DR; Busby WH; Arai T; Nam TJ; Clarke JB; Jones JI; Ankrapp DK
Prog Growth Factor Res; 1995; 6(2-4):357-66. PubMed ID: 8817679
[TBL] [Abstract][Full Text] [Related]
15. The carboxy-terminal domain of IGF-binding protein-5 inhibits heparin binding to a site in the central domain.
Song H; Shand JH; Beattie J; Flint DJ; Allan GJ
J Mol Endocrinol; 2001 Jun; 26(3):229-39. PubMed ID: 11357059
[TBL] [Abstract][Full Text] [Related]
16. The interaction of insulin-like growth factor-I with the N-terminal domain of IGFBP-5.
Zesławski W; Beisel HG; Kamionka M; Kalus W; Engh RA; Huber R; Lang K; Holak TA
EMBO J; 2001 Jul; 20(14):3638-44. PubMed ID: 11447105
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor binding protein-5 binds to plasminogen activator inhibitor-I.
Nam TJ; Busby W; Clemmons DR
Endocrinology; 1997 Jul; 138(7):2972-8. PubMed ID: 9202242
[TBL] [Abstract][Full Text] [Related]
18. Role of N- and C-terminal residues of insulin-like growth factor (IGF)-binding protein-3 in regulating IGF complex formation and receptor activation.
Yan X; Forbes BE; McNeil KA; Baxter RC; Firth SM
J Biol Chem; 2004 Dec; 279(51):53232-40. PubMed ID: 15485880
[TBL] [Abstract][Full Text] [Related]
19. Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix.
Arai T; Busby W; Clemmons DR
Endocrinology; 1996 Nov; 137(11):4571-5. PubMed ID: 8895319
[TBL] [Abstract][Full Text] [Related]
20. Complex with a phage display-derived peptide provides insight into the function of insulin-like growth factor I.
Schaffer ML; Deshayes K; Nakamura G; Sidhu S; Skelton NJ
Biochemistry; 2003 Aug; 42(31):9324-34. PubMed ID: 12899619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]